ZBTB16::RARA variant acute promyelocytic leukemia (vAPL) treated with gemtuzumab ozogamicin (GO) with unique pathology and genetic findings

Br J Haematol. 2023 Sep;202(6):1077-1078. doi: 10.1111/bjh.18950. Epub 2023 Jul 26.

Authors

Alaa M Kassem^{1

2}, Melissa C Keinath^{1

3}, Jason A Adler^{4

5}, Ramya Gadde^{3

4}, Benjamin K Tomlinson^{4

5}, Shashirekha Shetty^{1

3

4}

Affiliations

¹ Center for Human Genetics, University Hospitals Cleveland Medical Center.
² Clinical Pathology Department, Faculty of Medicine, Assiut University, Egypt.
³ Department of Pathology, University Hospitals Cleveland Medical Center.
⁴ Case Western Reserve University School of Medicine.
⁵ Department of Hematology, University Hospitals Cleveland Medical Center.

PMID: 37495505
DOI: 10.1111/bjh.18950

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aminoglycosides
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized / therapeutic use
Gemtuzumab / therapeutic use
Humans
Leukemia, Myeloid, Acute*
Leukemia, Promyelocytic, Acute* / drug therapy
Leukemia, Promyelocytic, Acute* / genetics
Leukemia, Promyelocytic, Acute* / pathology
Promyelocytic Leukemia Zinc Finger Protein

Substances

Gemtuzumab
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal
Aminoglycosides
ZBTB16 protein, human
Promyelocytic Leukemia Zinc Finger Protein